<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01287793</url>
  </required_header>
  <id_info>
    <org_study_id>B1811062</org_study_id>
    <nct_id>NCT01287793</nct_id>
  </id_info>
  <brief_title>Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects</brief_title>
  <official_title>Randomized, 4-Way, Crossover Single Dose, Placebo And Active Controlled Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Administration of a single 50 mg or 200 mg dose of tigecycline will not cause a change in
      QT/QTc intervals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      evaluation of effect of tigecycline on QT/QTc in healthy volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in serial QTc measurements in healthy volunteers up to 96 hours after single tigecycline doses</measure>
    <time_frame>Up to 96 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTc, using Fredericia's correction at each time point during moxifloxacin treatment periods</measure>
    <time_frame>-2.5, -2, -1.5, -1, 0, 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration pharmacokinetic endpoint for tigecycline</measure>
    <time_frame>-1, 0, 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration pharmacokinetic endpoint for tigecycline</measure>
    <time_frame>-1, 0, 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate constant pharmacokinetic endpoint for tigecycline</measure>
    <time_frame>-1, 0, 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life pharmacokinetic endpoint for tigecycline</measure>
    <time_frame>-1, 0, 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve to last measured concentrations pharmacokinetic endpoint for tigecycline</measure>
    <time_frame>-1, 0, 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve extrapolated to infinity pharmacokinetic endpoint for tigecycline</measure>
    <time_frame>-1, 0, 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance pharmacokinetic endpoint for tigecycline</measure>
    <time_frame>-1, 0, 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady-state pharmacokinetic endpoint for tigecycline</measure>
    <time_frame>-1, 0, 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response-exposure relationships between QT/QTc and tigecycline concentration</measure>
    <time_frame>-1, 0, 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>high dose tigecycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>regular dose tigecycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tigecycline</intervention_name>
    <description>intravenous, 200 mg, single dose</description>
    <arm_group_label>high dose tigecycline</arm_group_label>
    <other_name>Tygacil, GAR-936</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tigecycline</intervention_name>
    <description>intravenous, 50 mg, single dose</description>
    <arm_group_label>regular dose tigecycline</arm_group_label>
    <other_name>Tygacil, GAR-936</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin</intervention_name>
    <description>oral tablet, 400 mg, single dose</description>
    <arm_group_label>moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mL 0.9% Sodium Chloride intravenous</intervention_name>
    <description>intravenous fluid, 100 mL, single dose</description>
    <arm_group_label>moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>0.9% Sodium Chloride intravenous 100mL, single dose</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  Body mass index 17.5 - 30.5 kg

          -  Total body weight greater than 50 kg

        Exclusion Criteria:

          -  Recent history of diarrhea

          -  Use of oral antibiotics in the last 2 weeks

          -  History of risk factors for QT prolongation pregnant females

          -  Nursing females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1811062&amp;StudyName=Study%20To%20Evaluate%20The%20Effect%20Of%20Single%20Intravenous%20Doses%20Of%20Tigecycline%20On%20QTc%20Intervals%20In%20Healthy%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2011</study_first_submitted>
  <study_first_submitted_qc>January 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2011</study_first_posted>
  <last_update_submitted>May 23, 2011</last_update_submitted>
  <last_update_submitted_qc>May 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Tigecycline</mesh_term>
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

